Literature DB >> 19435854

Oligomeric resistin impairs insulin and AICAR-stimulated glucose uptake in mouse skeletal muscle by inhibiting GLUT4 translocation.

Sebastian Beck Jørgensen1, Jane Honeyman, Jonathan S Oakhill, Daniel Fazakerley, Jacqueline Stöckli, Bruce E Kemp, Gregory R Steinberg.   

Abstract

The hormone resistin is elevated in obesity and impairs glucose homeostasis. Here, we examined the effect of oligomerized human resistin on insulin signaling and glucose metabolism in skeletal muscle and myotubes. This was investigated by incubating mouse extensor digitorum longus (EDL) and soleus muscles and L6 myotubes with physiological concentrations of resistin and assessing insulin-stimulated glucose uptake, cellular signaling, suppressor of cytokine signaling 3 (SOCS-3) mRNA, and GLUT4 translocation. We found that resistin at a concentration of 30 ng/ml decreased insulin-stimulated glucose uptake by 30-40% in soleus muscle and myotubes, whereas in EDL muscle insulin-stimulated glucose uptake was impaired at a resistin concentration of 100 ng/ml. Impaired insulin-stimulated glucose uptake was not associated with reduced Akt phosphorylation or IRS-1 protein or increased SOCS-3 mRNA expression. To further investigate the site(s) at which resistin impairs glucose uptake we treated myotubes and skeletal muscle with the AMPK activator 5-aminoimidazole-4-carboxamide-1-beta-4-ribofuranoside (AICAR) and found that, although resistin did not impair AMPK activation, it reduced AICAR-stimulated glucose uptake. These data suggested that resistin impairs glucose uptake at a point common to insulin and AMPK signaling pathways, and we thus measured AS160/TBC1D4 Thr(642) phosphorylation and GLUT4 translocation in myotubes. Resistin did not impair TBC1D4 phosphorylation but did reduce both insulin and AICAR-stimulated GLUT4 plasma membrane translocation. We conclude that resistin impairs insulin-stimulated glucose uptake by mechanisms involving reduced plasma membrane GLUT4 translocation but independent of the proximal insulin-signaling cascade, AMPK, and SOCS-3.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19435854     DOI: 10.1152/ajpendo.90744.2008

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  17 in total

1.  Knockdown of NYGGF4 increases glucose transport in C2C12 mice skeletal myocytes by activation IRS-1/PI3K/AKT insulin pathway.

Authors:  Xue-Qi Zeng; Chun-Mei Zhang; Mei-Ling Tong; Xia Chi; Xi-Ling Li; Chen-Bo Ji; Rong Zhang; Xi-Rong Guo
Journal:  J Bioenerg Biomembr       Date:  2012-04-18       Impact factor: 2.945

Review 2.  Interorgan Communication Pathways in Physiology: Focus on Drosophila.

Authors:  Ilia A Droujinine; Norbert Perrimon
Journal:  Annu Rev Genet       Date:  2016-10-10       Impact factor: 16.830

Review 3.  AMPK inhibition in health and disease.

Authors:  Benoit Viollet; Sandrine Horman; Jocelyne Leclerc; Louise Lantier; Marc Foretz; Marc Billaud; Shailendra Giri; Fabrizio Andreelli
Journal:  Crit Rev Biochem Mol Biol       Date:  2010-08       Impact factor: 8.250

Review 4.  The role of resistin in inflammatory myopathies.

Authors:  Mária Filková; Ladislav Senolt; Jiří Vencovský
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.592

5.  Resistin disrupts glycogen synthesis under high insulin and high glucose levels by down-regulating the hepatic levels of GSK3β.

Authors:  Rongjing Song; Xi Wang; Yiqing Mao; Hui Li; Zhixin Li; Wei Xu; Rong Wang; Tingting Guo; Ling Jin; Xiaojing Zhang; Yizhuang Zhang; Na Zhou; Ruobi Hu; Jianwei Jia; Zhen Lei; David M Irwin; Gang Niu; Huanran Tan
Journal:  Gene       Date:  2013-07-13       Impact factor: 3.688

6.  Metabolic cross-talk between skeletal muscle and adipose tissue in high-intensity interval training vs. moderate-intensity continuous training by regulation of PGC-1α.

Authors:  Hossein Shirvani; Ehsan Arabzadeh
Journal:  Eat Weight Disord       Date:  2018-02-26       Impact factor: 4.652

7.  Reduced AMP-activated protein kinase activity in mouse skeletal muscle does not exacerbate the development of insulin resistance with obesity.

Authors:  S Beck Jørgensen; H M O'Neill; K Hewitt; B E Kemp; G R Steinberg
Journal:  Diabetologia       Date:  2009-08-18       Impact factor: 10.122

8.  β2-adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling.

Authors:  Robert A Ngala; Jacqueline F O'Dowd; Claire J Stocker; Michael A Cawthorne; Jonathan R S Arch
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2013-04-06       Impact factor: 3.000

9.  Central glucocorticoid administration promotes weight gain and increased 11β-hydroxysteroid dehydrogenase type 1 expression in white adipose tissue.

Authors:  Christelle Veyrat-Durebex; Nicolas Deblon; Aurélie Caillon; Ruth Andrew; Jordi Altirriba; Alex Odermatt; Françoise Rohner-Jeanrenaud
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240

10.  Deletion of skeletal muscle SOCS3 prevents insulin resistance in obesity.

Authors:  Sebastian Beck Jorgensen; Hayley M O'Neill; Lykke Sylow; Jane Honeyman; Kimberly A Hewitt; Rengasamy Palanivel; Morgan D Fullerton; Lisa Öberg; Anudharan Balendran; Sandra Galic; Chris van der Poel; Ian A Trounce; Gordon S Lynch; Jonathan D Schertzer; Gregory R Steinberg
Journal:  Diabetes       Date:  2012-09-06       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.